Glycosaminoglycans (GAGs), such as chondroitin sulfate and hyaluronic acid, have been researched for their potential role in the management of musculoskeletal injuries, including sprains. GAGs are long, unbranched polysaccharides that are key components of the extracellular matrix in connective tissues. Their main physiological functions include providing structural support, maintaining hydration, and modulating cell signaling involved in tissue repair.

Some scientific studies have investigated the use of GAGs—either alone or in combination with other substances (e.g., glucosamine, collagen)—for supporting joint and soft tissue healing. Preclinical (animal) studies suggest that exogenous GAGs may help reduce inflammation and promote repair of ligaments and tendons. For example, supplementation has shown to modulate inflammatory cytokines and enhance collagen synthesis in models of ligament injury.

However, high-quality randomized controlled trials (RCTs) in humans specifically evaluating the efficacy of GAGs for treating sprains are limited. Most clinical data focus on osteoarthritis and chronic joint conditions rather than acute ligamentous injuries like sprains. Some small studies and anecdotal reports suggest benefits in pain reduction and functional recovery, but the evidence remains insufficient and somewhat inconsistent.

In summary, while there is a scientific rationale and some preliminary evidence for using glycosaminoglycans to support recovery from sprains, robust clinical validation is lacking, and the overall evidence level is modest (rated 2/5).